REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 50.70
Bid: 50.60
Ask: 50.80
Change: 1.00 (2.01%)
Spread: 0.20 (0.395%)
Open: 49.50
High: 51.00
Low: 49.50
Prev. Close: 49.70
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Joint venture with China Everbright to launch fund

28 May 2021 10:00

RNS Number : 1087A
IP Group PLC
28 May 2021
 

FOR RELEASE ON

28 May 2021

 

IP Group plc forms joint venture with China Everbright Ltd to

launch a £167m* (RMB1.5bn) fund in China

 

IP Group plc (LSE:IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, is delighted to announce a joint venture with China Everbright Limited (HKG:0165) in Hong Kong to launch a fund in China aimed at providing growth capital to China-based subsidiaries of IP Group's UK portfolio companies.

 

The fund, which can only invest in entities incorporated in the PRC such as the China subsidiaries of overseas companies or joint venture structures, is expected to achieve a first close of RMB500m (c.£56 million*) later this year and increase to RMB1.5bn (c. £167 million*) within the next three years.

 

Aimed at supporting high-growth companies wanting to establish a presence in China, the fund will deploy no less than 40% of the capital to IP Group plc portfolio companies with the balance available to non-IP Group deep technology companies. 

 

Alan Aubrey, Chief Executive of IP Group plc, said: "We are delighted to partner with one of the most renowned asset management firms in Greater China to support the growth of our portfolio companies in the region. This joint venture is consistent with our stated strategy of working with high-quality partners to provide our companies with access to expertise, network and capital."

 

Dr Wei Zhao, Chairman of China Everbright, said: "China Everbright has always been committed to the cultivation of high-growth technology businesses with its unique cross-border approach. We look forward to working with IP Group plc to enable world-class science and technology to make contributions to humanity."

The fund will be managed from the IP Group side by Dr Lewis Zhenyu Liu, Managing Director of IP Group Greater China and Managing Partner of IPG-CEL China Ventures, and Joyce Dan Xie, Managing Director of IP Group Greater China and Partner of IPG-CEL China Ventures. China Everbright is IP Group's exclusive partner in the RMB fund management business in China.

Dr Lewis Zhenyu Liu, Managing Director of IP Group Greater China and Managing Partner of IPG-CEL China Ventures, said: "The joint venture is dedicated to providing both financial and strategic support to deep technology businesses with unparalleled growth opportunities in one of the world's most dynamic economies."

* GBP equivalents calculated using 9 CNY/GBP.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Greg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

Dr Lewis Zhenyu LiuJoyce Dan Xie

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

lewis.liu@ipgroupgc.com

joyce.xie@ipgroupgc.com

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

About China Everbright Limited

China Everbright Limited was established in Hong Kong in 1997 and is China's leading cross-border investment and asset management company. Its parent company is China Everbright Group. Everbright manages private equity funds, venture capital funds, industry funds, mezzanine funds, parent funds, fixed income and equity funds. Everbright utilises its strong private capital and cultivates a number of high-growth-potential enterprises together with its investors.

 

ENDS

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADKOBKFBKDCPB
Date   Source Headline
17th Jun 20217:00 amRNSPortfolio company Apollo Therapeutics raises $145m
15th Jun 20218:00 amRNSFurther re Scrip Dividend
9th Jun 202111:29 amRNSResult of AGM
9th Jun 20217:00 amRNSAGM Statement
7th Jun 20217:00 amRNSPortfolio co Iksuda completes $42m financing round
28th May 20213:36 pmRNSDirector/PDMR Shareholding
28th May 202110:00 amRNSJoint venture with China Everbright to launch fund
27th May 20217:00 amRNSPortfolio co Pulmocide completes $92m Series C
26th May 20212:44 pmRNSUpdate on AGM
20th May 202110:01 amRNSScrip Dividend Reference Price
17th May 202112:44 pmRNSAdditional fair value gain of £20m
12th May 202112:08 pmRNSHolding(s) in Company
10th May 202111:15 amRNSInvestor webinars
6th May 20216:13 pmRNSNotice of AGM, Annual Report, Scrip Dividend
6th May 20215:55 pmRNSLTIP & DBSP awards; Director/PDMR shareholding
5th May 20217:00 amRNSPortfolio company Kuur acquired by Athenex
5th May 20217:00 amRNSPortfolio company Inivata acquired by NeoGenomics
4th May 20217:00 amRNSPortfolio company Oxford Nanopore raises £195m
7th Apr 202111:27 amRNSDirector/PDMR Shareholding
31st Mar 20219:15 amRNSHolding(s) in Company
30th Mar 20217:05 amRNSOxford Nanopore announces preparing for IPO in H2
26th Mar 202112:26 pmRNSEMA positive opinion for Diurnal's Chronocort
10th Mar 20217:00 amRNSAnnual Results
4th Mar 20216:07 pmRNSHolding(s) in Company
2nd Mar 202112:03 pmRNSHolding(s) in Company
24th Feb 202110:33 amRNSNotice of Results
18th Feb 20214:31 pmRNSHolding(s) in Company
18th Feb 20218:00 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSPortfolio company ApcinteX acquired by Centessa
10th Feb 20217:00 amRNSIP Group, Inc. raises $50.0m (£36.5m*) of funding
9th Feb 20213:52 pmRNSHolding(s) in Company
2nd Feb 20215:15 pmRNSHolding(s) in Company
11th Jan 20215:29 pmRNSHolding(s) in Company
6th Jan 20214:57 pmRNSPortfolio co Hinge Health completes $300m round
6th Jan 202111:34 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSPortfolio co Oxbotica completes £36m funding round
4th Dec 202011:41 amRNSHolding(s) in Company
3rd Dec 20208:01 amRNSArtios and Merck in global strategic collaboration
25th Nov 20207:00 amRNSDirector Declaration
23rd Nov 20205:05 pmRNSHolding(s) in Company
21st Oct 20207:00 amRNSInvestor webinar
13th Oct 20207:00 amRNSOxford Nanopore funding round and contract win
9th Oct 20209:46 amRNSOxford Nanopore's LamPORE test gains CE-IVD mark
7th Oct 20207:00 amRNSEnterprise Therapeutics' program acquired by Roche
23rd Sep 20201:40 pmRNSHolding(s) in Company
15th Sep 202012:07 pmRNSSecond Price Monitoring Extn
15th Sep 202012:02 pmRNSPrice Monitoring Extension
7th Sep 202012:07 pmRNSSecond Price Monitoring Extn
7th Sep 202012:02 pmRNSPrice Monitoring Extension
1st Sep 20205:18 pmRNSForm 8.3 - Modern Water plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.